Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

HER3 is a pseudokinase member of the EGFR family having a role in both tumor progression and drug resistance. Although HER3 was discovered more than 30 years ago, no therapeutic interventions have reached clinical approval to date. Because the evidence of the importance of HER3 is accumulating, increased amounts of preclinical and clinical trials with HER3-targeting agents are emerging. In this review article, we discuss the most recent HER3 biology in tumorigenic events and drug resistance and provide an overview of the current and emerging strategies to target HER3.

Automated summary

HER3, a pseudokinase member of the EGFR family, plays a crucial role in tumor progression and drug resistance. Despite being discovered over 30 years ago, therapeutic interventions targeting HER3 have not yet received clinical approval, leading to increasing preclinical and clinical trials.